Now I have all the evidence I need. Let me construct the final consolidated review.

---

## Summary

YAIB (Yet Another ICU Benchmark) is a modular, extensible framework for reproducible clinical ML on ICU data, supporting five major open-access datasets (MIMIC-III/IV, eICU, HiRID, AUMC) through a unified pipeline from cohort definition to model evaluation. The paper provides extensive baselines (6 model architectures × 5 tasks × 4 datasets) and uses the framework to demonstrate that seemingly minor choices in cohort definition, feature sets, and task definitions can affect predictive performance more than model class selection.

## Strengths

- **First harmonized multi-dataset benchmark for ICU prediction.** YAIB natively supports five major open-access ICU datasets through a single pipeline, whereas every existing ICU benchmark (Table 1) is limited to one or two datasets. This directly addresses the self-enforcing bias toward single-center US populations noted in the introduction and enables cross-dataset comparability that was previously impractical.

- **Empirically demonstrates that cohort definitions and preprocessing choices often affect performance more than model class.** The paper provides controlled experiments (Tables 4–6) showing: changing mortality exclusion criteria (≥24 h vs. ≥30 h) shifts AUROC by 3–4 points on HiRID; omitting dynamic features drops LR AUROC by up to 19%; switching sepsis definitions alters GRU AUROC from 89% to 79% on MIMIC-IV. These findings concretely support the paper's claim that standardized pipelines are urgently needed because "fair comparison" is currently impossible across studies.

- **Design prioritizes extensibility over rigid benchmarking.** The framework is built with a modular four-step architecture (clinical concepts → cohort & task → preprocessing → training/evaluation, Figure 1) and uses dataset-independent cohort definitions via the `ricu` R package. Unlike all prior benchmarks (Table 1, rows "Extensible" and "Dataset interoperability"), YAIB explicitly allows users to add datasets, tasks, models, and preprocessing steps without rewriting core code.

- **Provides the first benchmarks for the AUMC dataset.** The paper reports baseline results for AUMC across all five tasks (Tables 2–3), extending the reach of clinical ML to a European cohort that was previously unbenchmarked.

- **Demonstrates practical transfer-learning utility.** Using YAIB's harmonized format, the paper shows cross-dataset external validation (Figure 2) and fine-tuning experiments (Figure 3) where pre-training on eICU and fine-tuning on <4,000 HiRID samples consistently outperforms training from scratch.

## Weaknesses

### Fatal

None.

### Major

None. The paper makes reasonable contributions for a benchmark/tool paper and supports them with appropriate experiments.

### Minor

- **Ambiguous description of the hyperparameter tuning procedure (Section 4.1).** The text states: *"hyperparameter tuning used only the first 2/3 folds, respectively"* paired with *"30/50 (DL/ML, respectively) iterations."* While the intended meaning is likely "the first 2 folds for DL and the first 3 folds for ML," the notation "2/3 folds" is unclear — it could be read as "two-thirds of the folds" (which would be fractional) or as "2 folds for DL and 3 folds for ML." The description should be self-contained in the main text rather than requiring readers to infer from context or consult the (stripped) appendix. That said, the final validation of the best hyperparameters uses all 5 folds (line 222), and the critic's speculation that this "obscures the validity of every reported score" is unwarranted hyperbole — it is a common cost-saving measure, not a fatal flaw.

- **The fine-tuning experiment (Figure 3) is limited to a single source-target pair and a single task.** The claim that "fine-tuning was profitable for any number of samples" rests on one curve (eICU → HiRID, mortality) without confidence intervals. While the result is suggestive and useful, the paper would benefit from additional source-target pairs and/or tasks to support generalization.

- **The evidence for the headline claim about preprocessing/cohort > model class could be more systematic.** The core experiments (cohort change on HiRID, feature ablation, sepsis definition comparison) each demonstrate the effect on a single task or dataset. A variance decomposition (e.g., ANOVA partitioning variance explained by model class vs. dataset vs. cohort definition) across the full experimental matrix would make the headline claim rigorous. The current evidence is *suggestive* and supports the claim, but a more formal analysis would strengthen it.

### Trivial

- None significant.

## Nice-to-Haves

- A simple reproducibility check (running one YAIB experiment twice and confirming identical results) would directly verify the framework's core promise, even if such checks are not standard for benchmark papers.
- Exploring why certain model classes dominate specific tasks (e.g., GRU for AKI, Transformers for LOS) could yield interesting insights for the community.
- Including calibration plots or confusion matrices for at least one task would give readers a richer view of model behavior beyond threshold metrics.

## Removed Points

These points were raised by reviewers but do not withstand verification against the paper. They are listed here for transparency only.

- **"No validation that YAIB actually achieves its stated goals"** — The paper's stated goals are to provide a transparent, reproducible, and extensible framework; the paper validates this by demonstrating the framework in action across 4 datasets × 5 tasks × 6 models, including ablation and transfer-learning studies. Demanding user studies, setup-time measurements, or formal reproducibility tests goes beyond what is standard for a benchmark/tool paper.

- **"Headline claim not adequately supported by evidence"** — The paper provides multiple experiments (cohort exclusion on HiRID, feature ablation across datasets, sepsis definition on MIMIC-IV) that collectively support the claim. The critic's assertion that this is "a single comparison" misreads the paper; Table 4 shows one analysis, but Tables 6 and the feature ablation studies (in the appendix) provide additional supporting evidence across different axes.

- **"Missing external validation baseline: no model trained on all data pooled together"** — The pooled (d-1) model *is* trained on all data except the target, and is compared against single-dataset models (line 415: "The pooled model usually performed as well as the best single-dataset model"). This is an appropriate baseline. The critic appears to have misread the experiment.

- **"Reliance on R package not discussed"** — The paper explicitly addresses this (lines 145–146): "For users unfamiliar with R, we provide an interface to access ricu concepts directly from Python. pycu(), a native Python implementation of ricu, is in development."

- **"Discussion does not critically reflect on limitations"** — The discussion mentions limitations (lines 464–467): "YAIB is currently limited to ICU settings," notes that further harmonization is needed for medications and comorbidities, and advises clinical validation before practical use.

- **Reproducibility concerns about PAPER.md and appendices** — Per review policy, the paper references appendices and reproducibility files that exist in the original submission but were stripped by the parser. These concerns are not valid.

- **"Overstates the gap: existing benchmarks (Clairvoyance) are explicitly modular"** — The paper's Table 1 shows Clairvoyance as "Extensible" (✓). The paper's claim is about *dataset interoperability* and *end-to-end* support (data extraction through evaluation), not that no existing benchmark is extensible.

## Novel Insights

None beyond the paper's own contributions. The primary insight — that cohort/preprocessing choices often dominate model class in determining ICU prediction performance — is the paper's own empirical finding, validated across several settings. The reviewers do not add novel perspectives beyond this.

## Suggestions

1. Clarify the hyperparameter tuning description in Section 4.1 by replacing "first 2/3 folds, respectively" with explicit language (e.g., "first 2 folds for DL models and first 3 folds for ML models").
2. Add a variance decomposition analysis partitioning the contribution of model class vs. dataset vs. cohort definition vs. preprocessing to strengthen the headline claim.
3. Extend the fine-tuning experiment to at least one additional source-target pair to support the generality of the finding.

## Score and Decision

**Originality:** The framework is novel in its multi-dataset harmonization and extensibility, though it builds on existing benchmarks and the `ricu` package. The empirical finding that cohort/preprocessing choices dominate model class is a useful community contribution.

**Importance of research question:** The reproducibility and comparability crisis in ICU ML is well-recognized and important. A well-designed multi-dataset framework is a practical step forward.

**Claims supported:** The paper's core claims are supported — the framework demonstrably works, the baselines are comprehensive, and the ablation studies support the headline finding. The hyperparameter tuning description is the only methodological detail that needs clarification.

**Soundness of experiments:** The experimental design is sound. 5×5-fold cross-validation, standard preprocessing, and rigorous exclusion criteria are appropriate. The one unclear aspect (hyperparameter tuning on a subset of folds) is a minor concern.

**Clarity of writing:** Generally clear and well-structured. The design philosophy and framework architecture are well-explained.

**Value to community:** High for the clinical ML community — YAIB provides a practical tool that reduces the overhead of multi-dataset evaluation and enables standardized comparisons.

The paper has no fatal or major weaknesses. The minor issues (ambiguous tuning description, limited fine-tuning experiment, modestly supported headline claim) are addressable and do not undermine the paper's contributions. The paper makes a genuine practical contribution to the clinical ML community.

**Score: 7.0** — A solid paper that makes a useful contribution with appropriate validation. The framework fills a clear gap and the experiments are thorough.

MY FINAL SCORE: <pineapple>7.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>